Abstract
Background: Drug holidays' (DH) for metastatic colorectal cancer (mCRC) were introduced to preserve quality of life. We studied factors associated to a DH offer in first line. Materials methods: We retrospectively analyzed 754 consecutive patients treated with chemotherapy for mCRC in two Italian institutions between 2005 and 2017. Associations between baseline clinical-pathological factors and DH (56 or more days of treatment interruption) were investigated. Results: In 754 patients, previous metastasectomy, previous thermoablation and previous surgery of primary tumor were independently associated with DH. Excluding procedures or clinical trials: primary rectal cancer and resection of primary tumor were significantly associated to DH. Conclusions: DH was offered to patients with lower burden of disease, but further investigations are needed to safely guide a holiday strategy.
Original language | English |
---|---|
Pages (from-to) | 2645-2660 |
Number of pages | 16 |
Journal | Future Oncology |
Volume | 16 |
Issue number | 32 |
DOIs | |
Publication status | Published - Nov 2020 |
Keywords
- chemotherapy
- colorectal cancer
- drug holidays
- metastasis
ASJC Scopus subject areas
- Oncology
- Cancer Research